ArticleScientific reports2015
Bub1 is required for maintaining cancer stem cells in breast cancer cell lines.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 78 citations in OpenAlex.
- BUB signaling in cancer and molecular insights into targeted therapies.Communications biology · 2026Review
- BUB1 regulates cell proliferation and apoptosis in cervical cancer by AKT signaling and autophagosome-lysosome fusion via ACTN1.iScience · 2026Article
- BUB1 in cancer genetics and oncogenomics: from chromosomal instability to therapeutic vulnerabilities.Frontiers in genetics · 2026Review
- A noncanonical cytoplasmic role for BUB1 in restraining DNA damage-induced dsRNA accumulation and sensing within stress granules.Science immunology · 2025Article
- Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma.Cell death & disease · 2025Article
- MELK as a Mediator of Stemness and Metastasis in Aggressive Subtypes of Breast Cancer.International journal of molecular sciences · 2025Article
- BUB1, miR-495-3p, and E2F1/E2F8 axis is associated with poor prognosis of breast cancer patients and infiltration of Th2 cells in the tumor microenvironment.Cancer biomarkers : section A of Disease markers · 2025Article
- Identification of Novel lncRNAs Related to Colorectal Cancer Through Bioinformatics Analysis.BioMed research international · 2025Article
- DAB2IP loss in luminal a breast cancer leads to NF-κB-associated aggressive oncogenic phenotypes.JCI insight · 2024Article
- DTL promotes the growth and migration of melanoma cells through the ERK/E2F1/BUB1 axis.Scientific reports · 2024Article
- BUB1 as a novel marker for predicting the immunotherapy efficacy and prognosis of breast cancer.Translational cancer research · 2024Article
- BUB1 induces AKT/mTOR pathway activity to promote EMT induction in human small cell lung cancer.Scientific reports · 2024Article
- Baitouweng decoction suppresses growth of esophageal carcinoma cells through miR-495-3p/BUB1/STAT3 axis.World journal of gastrointestinal oncology · 2024Article
- Prognostic and Therapeutic Implications of Cell Division Cycle 20 Homolog in Breast Cancer.Cancers · 2024Article
- Proliferation-Related Features of the Human Mesenchymal Stem Cells Derived from Palatine Tonsils, Adipose Tissues, and Bone Marrow.Tissue engineering and regenerative medicine · 2023Article
- Article
- Protooncogenic Role ofBioMed research international · 2023Article
- Article
- Key signaling networks are dysregulated in patients with the adipose tissue disorder, lipedema.International journal of obesity (2005) · 2022Article
- Identification of key regulators associated with colon cancer prognosis and pathogenesis.Journal of cell communication and signaling · 2022Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a leading cause of death among women worldwide due to therapeutic resistance and cancer recurrence. Cancer stem cells are believed to be responsible for resistance and recurrence. Many efforts to overcome resistance and recurrence by regulating cancer stem cells are ongoing. Bub1 (Budding uninhibited by benzimidazoles 1) is a mitotic checkpoint serine/threonine kinase that plays an important role in chromosome segregation. Bub1 expression is correlated with a poor clinical prognosis in patients with breast cancer. We identified that depleting Bub1 using shRNAs reduces cancer stem cell potential of the MDA-MB-231 breast cancer cell line, resulting in inhibited formation of xenografts in immunocompromised mice. These results suggest that Bub1 may be associated with cancer stem cell potential and could be a target for developing anti-breast cancer stem cell therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.